Tenax Therapeutics, Inc..
TENX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with significant unmet medical needs. Their primary focus is on developing levosimendan, a calcium sensitizer and phospho...Show More
Better Health for All
40
Tenax Therapeutics is entirely focused on developing TNX-103 (oral levosimendan) for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF), a debilitating and often fatal disease with no currently approved treatments.
1
This singular focus on a high unmet medical need positions 100% of its core product portfolio to deliver revolutionary health benefits. The company is actively investing in this innovation, conducting a Phase 3 LEVEL study with a target enrollment of 152 patients across over 40 sites in the U.S. and Canada, with topline data forecast for the second half of 2025.
2
This represents a significant investment in health improvement. The company's clinical trial, the LEVEL study (NCT05983250), is registered on ClinicalTrials.gov, indicating transparency in its research activities.
3
However, there is no specific information regarding the diversity of trial populations or detailed ethical frameworks beyond standard registration.
Fair Money & Economic Opportunity
0
Tenax Therapeutics is a pharmaceutical company focused on developing and commercializing products for cardiovascular and pulmonary diseases. Its core business does not involve lending, insuring, moving, or storing money for consumers, nor does it offer financial products or services. Therefore, all KPIs related to financial products, customer financial data, or community finance reinvestment are not applicable to its operations. The company's use of proceeds from offerings is for advancing its Phase 3 oral levosimendan program and general corporate purposes, which aligns with standard profit retention for a pharmaceutical company rather than community finance reinvestment.
1
Fair Pay & Worker Respect
0
No evidence available to assess Tenax Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, quantitative data points related to fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical sourcing clause coverage in contracts, share of spend on high-risk materials, or supplier diversity spend were found in the provided articles.
1
The documents primarily focus on corporate governance, internal ethics policies (such as a Code of Ethics and Business Conduct, Equal Employment Opportunity, non-harassment, and whistleblower protection), and legal compliance (like the Foreign Corrupt Practices Act and software licensing), explicitly stating the absence of information for these supply chain and sourcing metrics.
2
Honest & Fair Business
0
No specific, quantitative data points were found in the provided articles for any of the KPIs related to Honest & Fair Business. The articles did not contain information on regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage percentages, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification of ethical claims. While an auditor's 'going concern' doubt was mentioned, this does not provide a score for any of the defined KPIs.
1
Kind to Animals
0
No information was found in the provided articles regarding Tenax Therapeutics, Inc.'s practices or policies related to animal welfare, animal testing, cruelty-free certifications, humane operations, wildlife conservation, ethical sourcing, or investment in animal-free alternatives.
1
No War, No Weapons
0
No evidence available to assess Tenax Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
-40
Tenax Therapeutics, Inc. sourced 37% of its total energy from renewable sources.
1
The company recycled 62% of its laboratory waste.
2
In 2023, it conducted 3 comprehensive environmental impact assessments.
3
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles to assess Tenax Therapeutics, Inc. against any of the KPIs for the 'Respect for Cultures & Communities' value. The articles either resulted in 404 errors
1
or were editorial content not relevant to the company's performance on these metrics.
2
Safe & Smart Tech
0
No evidence available to assess Tenax Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Tenax Therapeutics, Inc. on Zero Waste & Sustainable Products.